An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study toevaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide inpatients with essential hypertension.

• Conditions: essential hypertension; MedDRA version: 6.1Level: PTClassification code 10015488

• Registration Number: EUCTR2004-000240-25-IT
• Lead Sponsor: OVARTIS FARMA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-05-17
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 2685

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified